1-3 of 3
Will Savage, MDPhD
Close
Sort by
Journal Articles

DISC-0974, a Novel, First-in-Class, Anti-Hemojuvelin Monoclonal Antibody Is Predicted to be Efficacious at Low Doses in Humans As Determined By Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling in Non-Clinical Studies

Mark Hixon, PhD, Cecile Blaustein, PhD, Christopher King, PhD MBA, Sophia Nguyen, MS, Will Savage, MDPhD, Maria G. Beconi, PhD MS
Journal: Blood
Blood (2020) 136 (Supplement 1): 14–15.
https://doi.org/10.1182/blood-2020-138547
Published: 2020
Journal Articles

DISC-0974, a Novel, First-in-Class, Anti-Hemojuvelin Monoclonal Antibody Decreases Hepcidin and Increases Transferrin Saturation in a Non-Human Primate Model of Cytokine (IL-6) Induced Hypoferremia

Brian MacDonald, PhDMBBChir,MRCP, Cecile Blaustein, PhD, Sophia Nguyen, MS, Christopher King, PhD MBA, Vu Hong, PhD, Will Savage, MDPhD, Srikanth Venkatraman, PhD, Maria G. Beconi, PhD MS
Journal: Blood
Blood (2020) 136 (Supplement 1): 2.
https://doi.org/10.1182/blood-2020-138720
Published: 2020
Journal Articles

DISC-a, the First in a Novel Class of Potent and Selective Matriptase-2 Inhibitors for the Treatment of Hematologic Disorders Characterized By Low Hepcidin

Vu Hong, PhD, Ravi Krishna Babu, PhD, Cecile Blaustein, PhD, Sophia Nguyen, MS, Venkateshwar Rao, PhD, Will Savage, MDPhD, Brian MacDonald, PhDMBBChir,MRCP, Maria G. Beconi, PhD MS, Srikanth Venkatraman, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 41–42.
https://doi.org/10.1182/blood-2020-138509
Published: 2020